Baolingbao Biology Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020
Operating Revenue	2,685	2,392	2,516	2,713	2,755	2,041
Other Revenue	9.46	9.46	7.65	-	9.9	13.19
Revenue	2,695	2,402	2,524	2,713	2,765	2,055
Revenue Growth (YoY)	12.64%	-4.84%	-6.96%	-1.89%	34.58%	13.82%
Cost of Revenue	2,350	2,123	2,326	2,404	2,397	1,868
Gross Profit	344.84	278.47	197.52	308.4	368.24	186.77
Selling, General & Admin	128.16	106.05	106.5	129.8	122.17	105.09
Research & Development	14.53	9.54	11.3	8.46	12.58	11.2
Other Operating Expenses	23.55	15.66	15.74	15.95	16.33	13.79
Operating Expenses	172.17	134.77	137.74	151.82	155.21	131.41
Operating Income	172.67	143.7	59.78	156.58	213.03	55.37
Interest Expense	-10.91	-13.04	-22.68	-26.54	-16.95	-13.18
Interest & Investment Income	5.15	6.9	7.36	7.97	18.85	8.35
Currency Exchange Gain (Loss)	6.64	6.64	1.61	12.17	-4.28	-6.71
Other Non Operating Income (Expenses)	2.23	1.92	-3.09	-1.53	0.92	2.35
EBT Excluding Unusual Items	175.78	146.12	42.98	148.65	211.58	46.18
Gain (Loss) on Sale of Investments	-	-	-	2.61	11.23	-
Gain (Loss) on Sale of Assets	0	0.41	-0.05	-0.05	-	-0.07
Asset Writedown	-22.42	-22.56	0.01	-2.32	0.83	-0.07
Other Unusual Items	17.39	7.15	22.17	7.79	13.09	13.59
Pretax Income	170.76	131.11	65.11	156.69	236.74	59.63
Income Tax Expense	26.67	19.95	11.15	23.52	35.16	9.77
Earnings From Continuing Operations	144.09	111.16	53.97	133.17	201.58	49.86
Net Income	144.09	111.16	53.97	133.17	201.58	49.86
Net Income to Common	144.09	111.16	53.97	133.17	201.58	49.86
Net Income Growth	32.13%	105.97%	-59.47%	-33.94%	304.27%	41.52%
Shares Outstanding (Basic)	369	371	360	370	373	356
Shares Outstanding (Diluted)	369	371	360	370	373	356
Shares Change (YoY)	4.48%	2.99%	-2.74%	-0.91%	4.81%	1.08%
EPS (Basic)	0.39	0.30	0.15	0.36	0.54	0.14
EPS (Diluted)	0.39	0.30	0.15	0.36	0.54	0.14
EPS Growth	26.46%	100.00%	-58.33%	-33.33%	285.71%	40.00%
Free Cash Flow	102.37	58.79	130.05	-223.72	113.42	266.53
Free Cash Flow Per Share	0.28	0.16	0.36	-0.60	0.30	0.75
Dividend Per Share	0.060	0.095	0.080	0.080	0.060	0.060
Dividend Growth	-47.83%	18.75%	-	33.33%	-	100.00%
Gross Margin	12.80%	11.59%	7.83%	11.37%	13.32%	9.09%
Operating Margin	6.41%	5.98%	2.37%	5.77%	7.70%	2.70%
Profit Margin	5.35%	4.63%	2.14%	4.91%	7.29%	2.43%
Free Cash Flow Margin	3.80%	2.45%	5.15%	-8.25%	4.10%	12.97%
EBITDA	291.04	261.84	177.62	258.01	318.01	151.63
EBITDA Margin	10.80%	10.90%	7.04%	9.51%	11.50%	7.38%
D&A For EBITDA	118.37	118.14	117.84	101.43	104.98	96.26
EBIT	172.67	143.7	59.78	156.58	213.03	55.37
EBIT Margin	6.41%	5.98%	2.37%	5.77%	7.70%	2.70%
Effective Tax Rate	15.62%	15.22%	17.12%	15.01%	14.85%	16.38%
Revenue as Reported	2,695	2,402	2,524	2,713	2,765	2,055
Advertising Expenses	-	1.87	2.62	2.64	1.15	1.35

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.